Akeso Biopharma, shared on LinkedIn:
“Eexcited to share this Clinical Trials Arena feature on ivonescimab – a great look at its global clinical progress, market trajectory by GlobalData Healthcare, and the expanding scope of our development program.
Ivonescimab is now gaining momentum across multiple tumor types. Akeso, together with our partner Summit Therapeutics, Inc. is actively advancing the Phase III program to explore its full potential.”
You may also be interested in: Ivonescimab Plus Chemotherapy Shows Powerful Benefit After EGFR-TKI Resistance in Advanced Lung Cancer
